Allay Therapeutics Receives FDA Breakthrough Designation for ATX101 in Post-Knee Surgery Pain
Allay Therapeutics has announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation (BTD) to its lead investigational product, ATX101. This designation is for the treatment of post-surgical pain following total knee arthroplasty (TKA) in adults. The FDA’s decision was based on clinical data from a Phase 2 exploratory dose-ranging trial, which evaluated the product’s effectiveness in managing post-surgical pain following TKA procedures.
ATX101 is designed to provide extended pain relief for patients recovering from TKA surgeries. Unlike current pain management methods that only offer a few days of relief, ATX101 aims to reduce pain for weeks, enabling a more active recovery with less reliance on opioids and a lower risk of opioid-related side effects.
The FDA’s Breakthrough Therapy designation will allow Allay Therapeutics to work closely with the agency to accelerate the development and regulatory process for ATX101, including its eventual New Drug Application (NDA) filing. A Phase 2B registrational trial is planned to begin early next year at leading pain centres in the U.S.
The Breakthrough Therapy designation follows promising results from a Phase 2 exploratory trial (n=112), where ATX101 demonstrated sustained pain relief for up to four weeks following TKA surgery, compared to the standard of care. The trial also showed that ATX101 reduced opioid use and opioid-related side effects, with notable improvements in functional activities and patient satisfaction for up to 60 days post-surgery.
FDA’s Breakthrough Therapy programme is aimed at expediting the development of drugs for serious conditions where early clinical evidence suggests that the drug may offer significant improvement over current treatments. The designation grants access to additional guidance from the FDA, senior management involvement, and eligibility for rolling reviews to speed up the regulatory process.
ATX101 is an investigational treatment consisting of an approved sodium ion channel blocker, bupivacaine, combined with a biopolymer to provide prolonged pain relief after TKA, a common type of knee replacement surgery. The formulation delivers a high concentration of the drug in a compact form, allowing for sustained analgesia over several weeks. The treatment is administered at the end of surgery and dissolves naturally into water and carbon dioxide as it works. This simple procedure is designed to replace the current, more complex mix of pain management products used for short-term post-surgical relief. ATX101 has not yet been approved by the U.S. FDA.
